Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The product will be marketed by Dr. Reddy's Laboratories Inc.
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
The study met its primary endpoint and all 11 secondary efficacy endpoints
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
HYMPAVZI’s safety profile was generally favorable
Subscribe To Our Newsletter & Stay Updated
